CClinicalTrials.gg
CompletedNCT05505578GamerFitUpdated May 1, 2025Results posted

A Digital Intervention to Improve Physical Activity and Sleep Behaviors in Youth With Psychiatric Diagnoses

An interventional study of GamerFit Condition and Comparator Condition in Psychiatric Diagnosis, sponsored by Pennington Biomedical Research Center. Completed at 2 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by Pennington Biomedical Research Center · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Study summary

The goal of "GamerFit" is to test the delivery of a theory-based mHealth app that utilizes social support, exergaming, and telehealth coaching to improve PA levels, sleep, and psychiatric symptoms among youth participants (ages 13-17 y) with PD. In order to aid future intervention optimization, up to 65 participants with at least one PD will be randomized, with 30-35 using the GamerFit app with weekly telehealth coaching sessions and 30-35 using a commercial healthy habits app as a comparator group

02

Conditions studied

  • Psychiatric Diagnosis
03

In context

Disease

1,327 studies on the registry are indexed under Disease; 596 are open to participants now.

This study's enrollment of 62 is below the median of 80 across 732 interventional studies indexed under Disease.

Browse Disease studies →

Lead sponsor

Pennington Biomedical Research Center is the lead sponsor of 277 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 13-17 years of age (child/participant)
  • At least one PD diagnosis (excluding eating disorders) confirmed by parent report of physician diagnosis (child/participant)
  • IQ≥85/no intellectual disability that precludes participation confirmed by parent report (child/participant)
  • Can understand verbal English-language exergaming instructions (child/participant)
  • Physically capable of exercise confirmed by parent report (child/participant)
  • Has access to a smart phone or compatible tablet (child/participant)
  • Willing to download and use the app (child/participant)
  • Willing and able to be present during telehealth coaching sessions (parent)
  • Can have a competent translator present during coaching sessions if not fluent in English (parent)

Exclusion criteria

Exclusion Criteria:

  • Families for whom the mPIs think the study and/or intervention is clinically/medically inappropriate (e.g. developmental delay, or emotional or cognitive difficulties, if the PI believes these factors will interfere with study/intervention participation)
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    GamerFit Condition

    Includes use of a Fitbit and exergaming devices, the GamerFit app, and weekly telehealth coaching sessions.

    Behavioral: GamerFit Condition

  • Active comparator
    Comparator Condition

    Youth assigned to the comparator condition (n=30-35) will receive a Fitbit device (same as the intervention condition) and the Fitbit account activated on their device (e.g. phone/tablet/computer). They will receive instructions on using the PA and sleep tracking features, as well as a booklet of healthy habit tips. They will receive reminders to charge, sync and review their Fitbit data for the duration of the intervention.

    Behavioral: Comparator Condition

Interventions

  • BehavioralGamerFit Condition

    Participants receive a Fitbit device, the GamerFit app on their mobile device, exergaming console and games (Nintendo Switch) (where applicable), and follow a 12-week exergaming curriculum provided by the app. Physical activity (PA) increases during the intervention up to 60 minutes/session. Other interventional aspects include weekly reminders, exercise and health related video materials, and weekly telehealth sessions with an intervention coach.

  • BehavioralComparator Condition

    Participants receive a Fitbit device, instructions on how to use it, and a booklet of healthy tips. They also get weekly reminders to charge, sync, and review their Fitbit data.

06

What researchers measure

Primary outcomes

  1. Feasibility of the App

    Percentage of live coaching sessions attended (i.e. average of the number of coaching sessions attended divided by total number of coaching sessions expected). Because this is a percentage of visits, standard deviations/standard errors are not provided. This data are measured within the group as a whole and not by participants individually.

    Time frame: 12 weeks

Secondary outcomes

  1. Physical Activity

    Change in average minutes of daily physical activity from baseline to 12 weeks (e.g. value at 12 weeks minus value at baseline).

    Time frame: 12 weeks

  2. Sleep

    Change in average minutes of daily sleep from baseline to 12 weeks (e.g. value at 12 weeks minus value at baseline).

    Time frame: 12 weeks

07

Results

Posted May 1, 2025

Participant flow

Participant flow — Overall Study
MilestoneGamerFit ConditionComparator Condition
Started3131
Completed2519
Not completed612

Outcome measures

PrimaryFeasibility of the App

Percentage of live coaching sessions attended (i.e. average of the number of coaching sessions attended divided by total number of coaching sessions expected). Because this is a percentage of visits, standard deviations/standard errors are not provided. This data are measured within the group as a whole and not by participants individually.

Time frame:
12 weeks
Reported as:
Number · percentage of visits completed
Feasibility of the App
percentage of visits completedGamerFit Condition
Feasibility of the App88
SecondaryPhysical Activity

Change in average minutes of daily physical activity from baseline to 12 weeks (e.g. value at 12 weeks minus value at baseline).

Time frame:
12 weeks
Reported as:
Mean · minutes per day
Physical Activity
minutes per dayGamerFit ConditionComparator Condition
Physical Activity20.12 ± 16.424.17 ± 18.63
SecondarySleep

Change in average minutes of daily sleep from baseline to 12 weeks (e.g. value at 12 weeks minus value at baseline).

Time frame:
12 weeks
Reported as:
Mean · minutes per day
Sleep
minutes per dayGamerFit ConditionComparator Condition
Sleep-6.5 ± 19.119.6 ± 21.4

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GamerFit Condition0/31 (0%)0/31 (0%)0/31 (0%)
Comparator Condition0/31 (0%)0/31 (0%)0/31 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)GamerFit ConditionComparator ConditionTotal
<=18 years313162
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)GamerFit ConditionComparator ConditionTotal
Female8715
Male232447
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GamerFit ConditionComparator ConditionTotal
Hispanic or Latino538
Not Hispanic or Latino262854
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GamerFit ConditionComparator ConditionTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American235
White252449
More than one race336
Unknown or Not Reported112
08

Study locations

2 sites
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
  • Merrimack College
    North Andover, Massachusetts 01845, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · May 15, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Data will be made available to external investigators/public on a case-by-case basis, to be approved by the mPIs, in accordance with institutional, state, and federal regulations. All data that are shared will be de-identified to protect participant privacy and confidentiality. We will also make sure the data and relevant documents are available to users only under a data-sharing agreement that includes guarantees that: 1) data is used for research purposes only; 2) data will be secured on a password protected computer; and 3) data will be deleted after analyses are completed. Data and datasets will be kept and available to share for at least three years following completion of the project, in accordance with NIH regulations. Both institutions (Merrimack College and PBRC) have internal processes for data sharing and transfer lead by PBRC's Office of Legal and Regulatory Compliance and in accordance with the Office of Computing Services.

Supporting information: Study protocol, Sap, Icf

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05505578
Lead sponsor
Pennington Biomedical Research Center
Collaborators
National Institutes of Health (NIH), Merrimack College
Responsible party
Amanda Staiano (Associate Professor, Pennington Biomedical Research Center) — Principal investigator
First posted
Aug 17, 2022
Start date
Jan 19, 2023
Primary completion
Mar 12, 2024
Completion
Mar 12, 2024
Results posted
May 1, 2025
Last update
May 1, 2025

Study contacts

Amanda E Staiano, PhD, MPP
principal investigator · Pennington Biomedical Research Center
April Bowling, MA, ScD
principal investigator · Merrimack College

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion